Executive summary
Establishing a labeled shelf life requires two tightly linked elements: (1) a stability-indicating analytical approach (validated or phase-appropriately qualified) that can assess the product in the presence of degradants/changes, and (2) a formal stability program on representative batches under ICH-defined storage conditions. For biologics, there is no single universal test; sponsors propose a stability-indicating profile (e.g., potency plus orthogonal physicochemical/biochemical methods) and use real-time, real-condition data to support storage statements and shelf life. Shelf life is set using trend/statistical evaluation per ICH Q1E.
What is a “stability-indicating method” for biologics/ATMPs?
- For biotechnological/biological products, there is no single stability-indicating assay; you propose a product-specific stability-indicating profile capable of detecting changes in identity, purity, and potency over time. At the time of submission, methods in the profile should be validated.
- Demonstrating “stability-indicating” typically involves stress/forced-degradation or stress testing to reveal likely degradation pathways and to validate the stability-indicating power of the procedures. (Stress types and intensity must be appropriate to the modality.)
- Potency testing is part of pivotal stability studies where applicable and should be tied to a suitable reference material program.
- Validation principles (e.g., specificity/selectivity, accuracy, precision, range, robustness) follow ICH Q2(R2) and are situated within the analytical lifecycle (ICH Q14).
Examples of attributes typically in scope (illustrative, modality-dependent):
- Recombinant proteins/antibodies: potency/bioactivity, aggregates/particles, charge/size variants, identity.
- Viral vectors (e.g., AAV, LV): potency/infectivity or transduction, genome integrity/titer, capsid integrity/ratio, identity, impurities (e.g., residual DNA/protein).
- Cell therapies: potency relevant to MoA, viability, identity/phenotype, purity (process-related), sterility/microbial safety.
(FDA’s gene therapy CMC guidance reinforces inclusion of stability protocols and data in Module 3; cell-based products include expectations such as viability criteria.)
Designing a formal stability study (ICH Q1A + Q5C for biologics)
Batches. Provide data on ≥3 primary batches representative of the final process for drug substance and drug product; real-time/real-condition data are the foundation for dating.
Storage conditions (chosen per modality/packaging):
- General case (room-temperature products): long-term 25 °C/60% RH or 30 °C/65% RH; accelerated 40 °C/75% RH; use intermediate 30 °C/65% RH as needed.
- Refrigerated products: long-term 5 °C ± 3 °C; accelerated 25 °C/60% RH.
- Frozen products: long-term −20 °C ± 5 °C (no standard accelerated; assess short-term excursions with targeted studies). Products stored below −20 °C are handled case-by-case.
Testing frequency / time points (typical): Long-term 0, 3, 6, 9, 12, 18, 24 months then annually as applicable; accelerated often 0, 3, 6 months. Programs for biologics should reflect expected shelf life and may adjust frequency appropriately.
What to test. Include attributes susceptible to change that could affect quality, safety, or efficacy, using validated stability-indicating methods (e.g., potency, purity/aggregates, identity, appearance, pH, microbial safety as applicable). In-use stability (e.g., after thaw/dilution/preparation) should be studied to support labeling.
Excursions & shipping. Use accelerated/intermediate data (and targeted short studies) to discuss short-term excursions outside label conditions (e.g., during shipping/handling).
Establishing shelf life
Shelf life is determined by evaluating trends and variability (e.g., regression with confidence limits) for each stability attribute per ICH Q1E. Extrapolation beyond long-term data is limited and must be justified; any extrapolated dating should be verified with subsequent real-time data. Shelf life cannot exceed what any single critical attribute supports.
Regulatory anchors (primary)
- ICH Q5C — Stability testing of biotechnological/biological products (biologics-specific principles; potency in stability; “stability-indicating profile”; batch and protocol expectations).
- ICH Q1A(R2) — Stability program design, storage conditions (general/refrigerated/frozen), intermediate/accelerated use, in-use studies, shipping excursions.
- ICH Q1E — Statistical evaluation of stability data and rules for extrapolation.
- ICH Q2(R2) — Validation framework placing specificity/selectivity and robustness of stability-indicating procedures within the analytical lifecycle.
- FDA (CBER) Gene Therapy CMC IND Guidance (2020) — Expects stability protocols and data in CTD Module 3; includes modality-specific considerations for gene and cell therapies.